The AI.ME non-surgical platform acts on the dermis in a priorly planned, selective and predictable way. Credit: Natálie Šteyerová from Pixabay.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to market Venus Concept’s AI.ME next generation robotic technology intended for fractional skin resurfacing.

Leveraging a visualisation system, machine vision and artificial intelligence (AI) algorithms, this non-surgical platform acts on the dermis in a priorly planned, selective and predictable way. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Up to 10% of skin in the treatment region is removed by utilising the technology’s array of micro-coring hollow punches to accurately core and remove micro-skin fractions at a particular depth.

This leads to the deposition of collagen and causes the treated area’s fractional skin resurfacing.

AI.ME is said to be the first-of-its-kind robotic system to provide physicians with less-invasive treatments for procedures with increased demand and require fractional skin resurfacing. 

See Also:

With the latest approval, the company plans to introduce the first AI.ME systems in the US next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Venus Concept CEO Rajiv De Silva said: “We see AI.ME as a versatile platform and we will continue to develop the platform to provide innovative solutions in various areas of medical aesthetics, starting with fractional skin resurfacing. 

“The AI.ME technology will be critical to maximising the synergy between our well-established medical aesthetic business and our pioneering robotics business driven by a robust R&D pipeline developed by our team in San Jose.” 

Apart from the AI.ME system, the product portfolio of the company comprises aesthetic device platforms, such as Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow and Venus Bliss among others. 

It also has hair restoration systems including NeoGraft and the ARTAS iX Robotic Hair Restoration system.